Home > Products > Linzolid
Share Print This Page

Linzolid (Linezolid)
Therapeutic Group: Anti Bacterial

Linzolid 600 Tablet: Each film-coated tablet contains Linzeolid INN 600 mg.

Linzolid Powder for Suspension: After reconstitution, each 5 ml suspension contains Linezolid INN 100 mg.

Linzolid 600 IV Infusion: Each 300 ml solution contains Linezolid INN 600 mg.

Linzolid (Linzolid) is a synthetic, antibacterial agent belonging to a new class of antibiotics, the oxazolidinones, with in vitro activity against Gram positive aerobic bacteria, some Gram positive anaerobic bacteria and certain Gram negative bacteria. It selectively inhibits bacterial protein synthesis via a mechanism of action different from that of other antibacterial agents. Linzolid binds to the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome and prevents the formation of a functional 70S initiation complex which is an essential component of the bacterial translation process. The results of time-kill studies have shown Linzolid to be bacteriostatic against enterococci and staphylococci. For streptococci, Linzolid was found to be bactericidal for the majority of strains.
• Vancomycin-Resistant Enterococcus faecium infections including cases with concurrent bacteremia.

• Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae (including multi-drug resistant strains). Combination therapy may be clinically indicated if the documented or presumptive pathogens include Gram-negative organism.

• Complicated skin and skin structure infections, including diabetic foot infections (without concomitant osteomyelitis) caused by Staphylococcus aureus (methicillin-susceptible and ¬resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae.

• Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes.

• Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains) including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only)
Dosage & Administration
Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as Linzolid (Linezolid) has an oral bioavailability of approximately 100%. The injection should be administered over a period of 30 to 120 minutes. The film coated tablets or oral suspension may be taken with or without food.
Adults and Adolescents (12 Years and Older):

• Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 10 to 14 days.
• Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 14-28
For Pediatric Patients (Birth through 11 Years of Age):
• Complicated skin and skin structure infections & Community-acquired pneumonia, including concurrent bacteremia: 600 mg IV or oral b.i.d. for 10 to 14 days.
• Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia: 600 mg IV or oral b.i.d.for 14-28.
Neonates < 7 days: Most pre-term neonates < 7 days of age (gestational age < 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg in every eight hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg t.i.d. by 7 days of life.
Side Effects
Most of the adverse events reported with Linzolid were mild to moderate in intensity. The most common adverse events in patients treated with Linzolid were diarrhea, headache and nausea. Other adverse included oral moniliasis, vaginal moniliasis, hypertension, dyspepsia, localized abdominal pain, pruritus, and tongue discoloration.
Patients who develop recurrent nausea or vomiting, unexplained acidosis, or low bicarbonate level while receiving Linzolid should receive immediate medical evaluation. Where administration of Linzolid and concomitant serotonergic agents is clinically appropriate, patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyper reflexia and incoordination. If signs or symptoms occur physicians should consider discontinuation of either one or both agents. If the concomitant serotonergic agent is withdrawn, discontinuation symptoms can be observed. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Convulsions have been reported in patients when treated with Linzolid. In some of these cases, a history of seizures or risk factors for seizures was reported.
Linzolid formulations are contraindicated for use in patients who have known hypersensitivity to Linzolid or any of the other product components. Linzolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. Linzolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome and/or patients taking directly and indirectly acting sympathomimetic agents (e.g. pseudoephedrine), vasopressive agents (e.g. epinephrine, norepinephrine), dopaminergic agents (e.g. dopamine, dobutamine), serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine or buspirone.
Use in Pregnancy & Lactation
Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Linzolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether Linzolid is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Linzolid is administered to a nursing woman.
Drug Interaction
Monoamine Oxidase Inhibition: Linzolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, Linzolid has the potential for interaction with adrenergic and serotonergic agents.
Adrenergic Agents: Some individuals receiving Linzolid may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.
Serotonergic Agents: Physicians should be alert to the possible signs and symptoms of serotonergic syndrome in patients receiving concomitant Linzolid and serotonergic agents.
No cases of overdose have been reported. Symptomatic and supportive care is advised together with maintenance of glomerular filtration. Approximately 30% of a Linzolid dose is removed during 3 hours of haemodialysis. No data are available for the removal of Linzolid by peritoneal dialysis or haemoperfusion.
Linzolid formulations should be stored at room temperature 25 °C, away from light and moisture. All medicines should be kept away from children.
Commercial Packaging
Linzolid 600 Tablet: Each box contains 10 tablets in blister pack.
Linzolid Powder for Suspension: After reconstitution, each 5 ml suspension contains Linezolid INN 100 mg.
Linzolid 600 IV Infusion: Each box contains 1 bottle of 300 ml solution for infusion & a hanger.
Reconstitution of Oral Suspension: Shake the bottle to loosen powder. Add 75 ml (with the help of given cup) of boiled & cooled water to the dry mixture in the bottle. For ease of preparation add water to the bottle in two portions. Shake well after each addition until all the powder is in suspension.
Note: Shake the suspension well before use. Keep the bottle tightly closed. The reconstituted suspension should be stored in a cool & dry place. Use within 21 days after reconstitution.

Intravenous Administration: Linzolid IV Injection is supplied in single-use, ready-to-use infusion bags. Parenteral drug products should be inspected visually for particulate matter prior to administration. Minute leaks should be checked by firmly squeezing the bag. If leaks are detected, the solution should be discarded, as sterility may be impaired. Linzolid IV Injection should be administered by intravenous infusion over a period of 30 to 120 minutes. The intravenous infusion bag should not be used in series connections. Additives should not be introduced into this solution. The infusion bag should be stored at room temperature and protected from freezing. Linzolid IV Injection may exhibit a yellow color that can intensify over time without adversely affecting potency.
Products from the same therapeutic group
Anti Bacterial
Cefadroxil Capsule 500 mg Powder for suspension Powder for paediatric drops
Amikacin injection
Aztreonam 1 gm for Injection (Sterile).
Ciprofloxacin Tablet, Suspensio & IV Infusion
Cefuroxime & Clavulanic Acid Tablet
Ceftibuten 400mg Capsule
Cefotaxime Injection
Imipenem USP 500 mg & Cilastatin USP 500 mg IV Injection
Clindamycin 150 & 300 mg capsule and 300 mg & 600 mg IV/IM Injection
Cefpodoxime+ Clavulanic acid Tablet
Cefixime Trihydrate USP
Erythromycin Tablets/Suspension
Meropenem Injection
Gentamicin Sulfate USP
Clarithromycin 250 and 500 mg Tablet
Levofloxacin 250, 500 & 750 mg tablets, 100 ml oral solution, 100 ml IV infusion.
Linezolid Tablet, Powder for Suspension and IV Infusion
Moxifloxacin Hydrochloride 400 mg Tablet
Neomycin Sulphate BP & Bacitracin Zinc USP
Nitrofurantoin tablet
Orasquin  Tablet
Gemifloxacin film coated tablet
Cefaclor Monohydrate Capsule/Dry suspension/Paediatric drops
Roxithromycin tablet/powder for suspension
Rifaximin 200 and 550 mg Tablet
Ceftazidime IV/IM
Tigecycline 50 mg as lyophilized powder for Infusion.
Spectinomycin IM Injection
Azithromycin Dihydrate USP
Cefpodoxime Proxetil Tablet/Suspension/Paediatric Drops/DS Suspension